Search stocks

Find any stock by ticker or company name

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Kuzatuv
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

NTLA - Intellia Therapeutics, Inc. So'nggi... | Finranks

Home

/

NTLA

I

Intellia Therapeutics, Inc. (NTLA)

NGM – Real vaqt narxi. Valyuta: USD

13.99

-0.43 (-2.98%)

Yopilishda: May 12, 2026, 4:00 PM EDT

14.17

+0.18 (1.29%)

Bozor oldidan: May 13, 2026, 6:19 AM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Intellia Therapeutics, Inc. (NTLA) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Intellia Therapeutics, Inc. (NTLA) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Intellia Therapeutics, Inc. (NTLA) Presents at Bank of America Global Healthcare Conference 2026 Transcript

NTLA Q1 Earnings Beat Estimates, Revenues Miss Mark, Pipeline in Focus

NTLA Q1 Earnings Beat Estimates, Revenues Miss Mark, Pipeline in Focus

Intellia cuts its Q1 loss, advances late-stage gene-editing programs and plans a 2027 launch for lonvo-z after strong phase III HAE data.

Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Misses Revenue Estimates

Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Misses Revenue Estimates

Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.92. This compares to a loss of $1.1 per share a year ago.

Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates

Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates

CAMBRIDGE, Mass., May 11, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today reported business updates and financial results for the first quarter ended March 31, 2026.

Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Intellia Therapeutics (NTLA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Ark Invest added to existing positions in Shopify, Intellia Therapeutics, and GeneDX on Tuesday. Shopify stock surrendered 16% of its value after posting disappointing quarterly results.

Intellia Therapeutics to Participate in Upcoming Investor Conferences

Intellia Therapeutics to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that management will be participating in fireside chats at the following upcoming investor conferences:

Videolar

No Data

There is no data to display

Press-relizlar

Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates

Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates

CAMBRIDGE, Mass., May 11, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today reported business updates and financial results for the first quarter ended March 31, 2026.

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on May 1, 2026, it awarded inducement grants to 43 new employees under Intellia's 2024 Inducement Plan, as amended, as a material inducement to employment.

Intellia Therapeutics Announces Pricing of Public Offering of Common Stock

Intellia Therapeutics Announces Pricing of Public Offering of Common Stock

CAMBRIDGE, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced the pricing of an underwritten public offering of 16,744,187 shares of its common stock. The shares of common stock are being sold at a public offering price of $10.75 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $180 million, excluding any exercise of the underwriters' option to purchase additional shares. All of the securities in the offering are to be sold by Intellia. In addition, Intellia has granted the underwriters a 30-day option to purchase up to 2,511,628 additional shares of its common stock at the public offering price, less the underwriting discounts and commissions.

Intellia Announces Proposed Public Offering of Common Stock

Intellia Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that it has commenced an underwritten public offering of $150 million of shares of its common stock. Intellia also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public offering. All of the shares in the proposed offering are to be sold by Intellia.